Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9589710 | 0.99 | AGTR1 (0.71) | AGTR1AGTR2 | |
| Potassium SCHEMBL9589729 | 0.99 | AGTR1 (0.71) | AGTR1AGTR2 | |
| SCHEMBL9589609 | 0.95 | AGTR1 (0.73) | AGTR1AGTR2 | |
| Methylamine SCHEMBL9590818 | 0.93 | AGTR1 (0.71) | AGTR1AGTR2 | |
| SCHEMBL9590003 | 0.93 | AGTR1 (0.72) | AGTR1AGTR2 | |
| SCHEMBL9589793 | 0.93 | AGTR1 (0.71) | AGTR1AGTR2 | |
| SCHEMBL9590889 | 0.92 | AGTR1 (0.65) | AGTR1AGTR2 | |
| Potassium Ion SCHEMBL9589716 | 0.91 | AGTR1 (0.60) | AGTR1AGTR2 | |
| SCHEMBL9424372 | 0.90 | AGTR1 (0.73) | AGTR1AGTR2 | |
| SCHEMBL9591506 | 0.90 | AGTR1 (0.73) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5250548-A | Treating hypertension, heart failure | ABBOTT LABORATORIES (US) | 1993-10-05 | — | — | US | claimed |
| EP-0475206-A2 | Angiotensin II receptor antagonists | ABBOTT LABORATORIES (US) | 1992-03-18 | — | — | EP | claimed |
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210361610-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2021-11-25 | — | — | US | disclosed |
| EP-3685833-A1 | COMPOUND COMPRISING AN ARB AND A NEPI | Novartis AG (CH) | 2020-07-29 | — | — | EP | disclosed |
| US-20200016109-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS AG (CH) | 2020-01-16 | — | — | US | disclosed |
| US-20160324821-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N--VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS AG (CH) | 2016-11-10 | — | — | US | disclosed |
| US-20160324821-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N--VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS AG (CH) | 2016-11-10 | — | — | US | disclosed |
| US-9388134-B2 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations | NOVARTIS, AG (CH) | 2016-07-12 | — | — | US | disclosed |
| US-9388134-B2 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations | NOVARTIS, AG (CH) | 2016-07-12 | — | — | US | disclosed |
| US-6218414-B1 | ADMINISTERING AN EFFECTIVE AMOUNT OF AN ANGIOTENSIN II ANTAGONIST AND A BENZOFURAN DERIVATIVE WITH ANTIARRHYTHMIC ACTIVITY FOR THERAPY OF CARDIOVASCULAR COMPLAINTS | SANOFI (FR) | 2001-04-17 | — | — | US | disclosed |
| US-6211175-B1 | P-AMINOMETHYLBENZOIC ACID DERIVATIVES; CARDIOVASCULAR DISORDERS; NONHYPOTENSIVE | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| EP-0686631-B1 | Pyrimidine derivatives and pharmaceutical compositions | KUREHA CHEMICAL IND CO LTD (JP) | 2001-01-17 | — | — | EP | disclosed |
| EP-0864568-A1 | Agents for treatment of cardiac diseases | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-09-16 | — | — | EP | disclosed |
| US-5585381-A | HYPOTENSIVE AGENT AND ALSO TREATING KIDNEY RENAL DISEASE | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-12-17 | — | — | US | disclosed |
| EP-0686631-A1 | Pyrimidine derivatives and pharmaceutical composition | Kureha Chemical Industry Co., Ltd. (JP) | 1995-12-13 | — | — | EP | disclosed |
| EP-0685470-A2 | Benzene derivatives and pharmaceutical composition | Kureha Chemical Industry Co., Ltd. (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5250548-A | Treating hypertension, heart failure | ABBOTT LABORATORIES (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0475206-A2 | Angiotensin II receptor antagonists | ABBOTT LABORATORIES (US) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324821-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N--VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, REN, AGTR1 | AGTR1 3/4885AGTR2 5/4885 |
| US-20210361610-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | AGTR1 4/4885AGTR2 7/4885 |
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | MME, DNPEP, AGTR1 | AGTR1 3/4885AGTR2 5/4885 |
| US-20200016109-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | AGTR1 4/4885AGTR2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.